The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs.

Late-Stage Products

We are poised for the market with a clinical pipeline that includes three novel products in late-stage development:

• BENLYSTA™ (belimumab) has successfully completed Phase 3 development in systemic lupus, and we expect the submission of marketing applications in the United States, Europe and other regions in the first half of 2010.
• ZALBIN™ (albinterferon alfa-2b) has successfully completed Phase 3 development in chronic hepatitis C. We have submitted a Biologics License Application to the FDA for ZALBIN in the United States and have received confirmation that our submission was accepted for filing with a PDUFA target date of October 4, 2010. Novartis has submitted a Marketing Authorization Application to the EMEA in Europe under the brand name JOULFERON®.
• In May 2009, we submitted a BLA to FDA for raxibacumab for the treatment of inhalation anthrax. We received a Complete Response Letter from the FDA in November 2009 and are working closely with the FDA to obtain approval.

We believe both BENLYSTA and ZALBIN have the therapeutic potential to change and save lives and, assuming regulatory approval, the commercial potential to become important products in the marketplace. Each is being co-developed and commercialized in collaboration with a world leader in the pharmaceutical industry – GlaxoSmithKline (GSK) for BENLYSTA and Novartis for ZALBIN.

Raxibacumab is being developed under a contract with the U.S. Government and represents a new way to address the threat of inhalational anthrax. In the first half of 2009, we achieved our first product sales by delivering 20,000 doses of raxibacumab to the U.S. Strategic National Stockpile for use in the event of an emergency to treat inhalation anthrax. In July 2009, we secured a new purchase order for 45,000 additional doses to be delivered over a three-year period. We delivered approximately 5,600 doses under the new order in fourth quarter 2009.

Mid-Stage Pipeline

Right behind these late-stage products is an emerging, high-potential mid-stage pipeline, led by mapatumumab, our TRAIL receptor antibody for cancer. We also have substantial financial rights to a number of products in the GSK clinical pipeline. GSK is currently conducting Phase 3 clinical trials of darapladib in men and women with chronic coronary heart disease and Syncria® (albiglutide) in patients with type 2 diabetes mellitus.

Manufacturing and Process Development

Our manufacturing and process development capability represents a significant strategic advantage. HGS is able to produce and purify multiple protein and antibody drugs in two state-of-the-art process development and manufacturing facilities – totaling approximately 400,000 square feet and offering both small-scale and large-scale production.

Strong Cash Position

Unlike many pre-commercial biopharmaceutical companies, HGS has built a strong cash position that allows us to focus on advancing our lead products toward commercialization as rapidly as possible, while at the same time investing in our early- and mid-stage pipeline. We are committed to achieving and sustaining growth well into the future.